← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Complement inhibitors
sutimlimab
L04AJ04
Forms & Strengths
- Intravenous solution: 1100 mg/22 mL (50 mg/mL) in a single-dose vial
Adult Dosing
- Body weight 39 kg to < 75 kg: 6,500 mg IV weekly for the first two doses, then every 2 weeks thereafter
- Body weight >= 75 kg: 7,500 mg IV weekly for the first two doses, then every 2 weeks thereafter
- Administer as an intravenous infusion over approximately 1 to 2 hours
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
Indications
- Treatment of hemolysis in adult patients with cold agglutinin disease (CAD)
Mechanism of Action
- Humanized monoclonal antibody that targets the complement protein C1s
- Inhibits the activation of the classical complement pathway
- Prevents C1-mediated opsonization and hemolysis of red blood cells in cold agglutinin disease
Contraindications
- Known hypersensitivity to sutimlimab-jome or any of its excipients
- Active systemic bacterial infections, particularly with encapsulated bacteria
Adverse Reactions
- Respiratory tract infections
- Nasopharyngitis
- Infusion-related reactions (e.g., dyspnea, flushing, tachycardia)
- Fatigue
- Diarrhea
- Peripheral edema
- Dizziness
- Headache
Drug Interactions
- Risk of serious infections with concurrent immunosuppressive therapies; monitor closely
- May diminish the therapeutic response to live vaccines; avoid administration of live vaccines during treatment
Curated Content: Needs Vetting Before Put to Clinical Use